newsfilter
← Latest News
GlobeNewswire·

European Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12